The spray – which was approved by the FDA in March – has a wholesale acquisition cost of $295 per 28 mg device and costs around $32,400 for a year’s treatment, says ICER.

Analysts at GlobalData have previously forecast that Spravato will generate global sales of approximately $383 million by 2029, with its potential pegged back by its cost and a requirement for two ...

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine ... and lead to increased healthcare costs. According to Johnson & Johnson, the ...

Kelsey Warren [email protected]  609 218 4053 Investor contact: Lauren Johnson [email protected] ...

On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name Spravato) nasal spray as a "monotherapy" treatment for major depressive ...

Q4 2024 Earnings Call Transcript February 7, 2025 Operator: Ladies and gentlemen, thank you for standing by. Welcome to ...

The bill does not include the cost of oral anti-depressants, which must accompany any Spravato course, and the talk therapy that doctors recommend. Patients usually have to continue on both ...

The bill does not include the cost of oral anti-depressants, which must accompany any Spravato course, and the talk therapy that doctors recommend. Patients usually have to continue on both ...

Vanessa Kanu Kanu; Executive Vice President and Chief Financial Officer; Aptargroup Inc Ladies and gentlemen, thank you for standing by. Welcome to Aptar 2024 fourth quarter and annual results ...

Esketamine (Spravato; Johnson & Johnson ... Nearly half of the total costs of MDD are attributable to TRD. "For more than six years, I've seen firsthand the real-world impact [esketamine] can ...

Spravato is a ketamine-derived nasal spray that ... Eldredge said his insurance covers the cost and he credits ketamine for his improved mental health. “It really was night and day difference ...